About
Ocular Therapeutix, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 29 2026
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Apr 28 2026
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Apr 27 2026
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Apr 22 2026
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Apr 13 2026
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
Translate